{"title":"Lasmiditan: the first neurally acting anti-migraine drug","authors":"S. Bhanwra, S. Mahajan, R. Kumar","doi":"10.18203/2319-2003.IJBCP20212088","DOIUrl":null,"url":null,"abstract":"Lasmiditan is the first neurally acting drug for the treatment of acute migraine. It is a highly selective, orally acting 5HT1F agonist that was approved in November 2019, for the acute treatment of migraine in adults, with or without aura, by USFDA. Lesmiditan may help in terminating the acute attack of migraine by inhibiting the central and peripheral neuronal activity and the release of CGRP.","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"41 1","pages":"745"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of basic and clinical pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/2319-2003.IJBCP20212088","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Lasmiditan is the first neurally acting drug for the treatment of acute migraine. It is a highly selective, orally acting 5HT1F agonist that was approved in November 2019, for the acute treatment of migraine in adults, with or without aura, by USFDA. Lesmiditan may help in terminating the acute attack of migraine by inhibiting the central and peripheral neuronal activity and the release of CGRP.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
